Prior studies have shown that targeting immune checkpoint molecules using anti–PD-1 and anti–CTLA-4 Ab have clinical activity in a fraction of AML patients after allo-HCT; however, aGVHD has limited the use of these Ab in the patients (13, 14, 60). The gene discussed is CTLA4; the disease is acute myeloid leukemia.